Fixed-dose combinations of antituberculous medications to prevent drug resistance

Annals of Internal Medicine

Volumn 122, Issue 12, 1995, Pages 951-954

  Moulding, Thomas ^a   Dutt, Asim K ^b   Reichman, Lee B ^c  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMATE; RIFAMPICIN; RIFATER;

ANTIBIOTIC RESISTANCE; DOSE RESPONSE; DRUG FORMULATION; DRUG LABELING; HUMAN; MYCOBACTERIUM TUBERCULOSIS; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS;

EID: 0029003888     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-122-12-199506150-00010     Document Type: Review

References (17)

1. Initial therapy for tuberculosis in the era of multidrug resistance. Recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR Morb Mortal Wkly Rep. 1993;42(RR-7):1-8.
2. British Medical Research Council. Treatment of pulmonary tuberculosis with streptomycin and para amino salicylic acid. Br Med J. 1950; 2:1073-85.
3. Fixed dose combinations of antimicrobiologic agents. N Engl J Med. 1969;280:1149-54.
4. Bass JB Jr, Farer LS, Hopewell PC, O'Brien R, Jacobs RF, Ruben F, et al. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and the Centers for Disease Control and Prevention. Am J Respir Crit Care Med. 1994;149:1359-74.
5. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council. Am Rev Respir Dis. 1991;143: 707-12.
6. Controlled trials of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service/British Medical Research Council. Am Rev Respir Dis. 1991; 143:700-6.
7. Geiter LJ, O'Brien RJ, Combs DL, Snider DE Jr. United States Public Health Service Tuberculosis Therapy Trial 21: preliminary results of an evaluation of a combination tablet of isoniazid, rifampin and pyrazinamide. Tubercle. 1987;68:41-6.
8. Combs DL, O'Brien RJ, Geiter LJ. USPHS Tuberculosis Short-course Chemotherapy Study Trial 21: effectiveness, toxicity, and acceptability. The report of final results. Ann Intern Med. 1990;112:397-406.
9. Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet. 1974; 2:1100-6.
10. East African Hospitals and Laboratories and British Medical Research Council. Comparative trial of isoniazid alone in low and high dosage and isoniazid plus PAS in the treatment of acute pulmonary tuberculosis in East Africans. Tubercle. 1960;41:83-102.
11. Davies PD. Tuberculosis in the United States [Letter]. Am Rev Respir Dis. 1993;147:497.
12. Mitchison DA. Basic mechanisms of chemotherapy. Chest. 1979;76(6 Suppl):771-80.
13. Glassroth J. Tuberculosis in the United States [Letter]. Am Rev Respir Dis. 1993;147:497.
14. Mahmoudi A, Iseman MD. Pitfalls in the care of patients with tuberculosis. Common errors and their association with the acquisition of drug resistance. JAMA. 1993;270:65-8.
15. Acocella G. Human bioavailablity studies. Bull Int Union Tuberc Lung Dis. 1989;64:38-40.
16. The promise and reality of fixed-dose combinations with rifampin. A joint statement of the International Union Against Tuberculosis and Lung Disease and the Tuberculosis Programme of the World Health Organization. Tuber Lung Dis. 1994;75:180-1.
17. Iseman MD, Cohn DL, Sbarbaro JA. Directly observed treatment of tuberculosis. We can't afford not to try it. N Engl J Med. 1993;328: 576-8.